We identified STAT3 and MEK/ERK/BCL2 as CKS1B-downstream signaling pathways; and thereby provided targets for the development of new therapeutic approaches for CKS1B over-expressing myeloma and other tumor malignancies. This evidence concerns the gene CKS1B and plasma cell myeloma.